Claudio Cerchione

1. Cerchione C, Fabbricini R, Pane F, Luciano L.

   Vitiligo-like lesions in an adult patient treated with Imatinib Mesylate

   Leuk Res.2009 Aug; 33(8): e104-5.

2. Pane F, Quintarelli F, Esposito N, Izzo B, De Angelis B, Peluso A, Muccioli Casadei G,

   Cosenza M, Cerchione C, Camera A, Luciano L.

   Acute and Chronic Ph+ Leukemias: differential leukemogenesis pathways translate into different clinical needs

   Hematologica, Vol.94, October 2009.

3. Cerchione C, Catalano L, Cerciello G, Avilia S, Picardi M, Risitano AM, Pisano I,

   Alfinito F, Pane F.

   Role of Lenalidomide in the management of myelodysplastic syndromes with del(5q)

   associated with pure red cell aplasia (PRCA)

   Ann Hematol. 2015 Mar; 94(3): 531-4.

4. Cerchione C, Catalano L, Pareto AE, Picardi M, Pane F.

   Pegfilgrastim in primary prophylaxis of febrile neutropenia during chemotherapy of relapsed and refractory multiple myeloma: a real-life experience

   Support Care Cancer. 2015 Feb; 23(2): 301-2.

5. Fonti R, Pace L, Cerchione C, Catalano L, Salvatore B, De Luca S, Pane F, Salvatore M, Del Vecchio S.

   18-FDG PET/CT, 99mTc-MIBI, and MRI in the prediction of outcome of patients with Multiple Myeloma: a comparative study

   Clin Nucl Med 2015 Apr; 40(4): 303-8

6. Cerchione C, Lucignano M, Pane F, Catalano L.

   Salvage therapy with pegylated liposomial doxorubicin-based regimen in relapsed/refractory multiple myeloma: comments to the article by Romano et al.

   Eur J Haematol. 2016 May; 96(5): 544.

7. Cerchione C, Catalano L, Peluso I, Nappi D, Di Perna M, Salvatore D, Migliaccio I, Picardi M, Pane F.

   Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone

   Support Care Cancer. 2016 Dec; 24(12): 4835-4837.

8. Cerchione C, De Renzo A, Di Perna M, Della Pepa R, Pugliese N, Catalano L, Pane F, Picardi M.

   Pegfilgrastim in primary prophylaxis of febrile neutropenia following front-line bendamustine plus rituximab treatment in patients with indolent non Hodgkin lymphoma: a single center, real-life experience

   Support Care Cancer. 2017 Mar; 25(3): 839-845.

9. Cerchione C, Nappi D, Di Perna M, Zacheo I, Pareto AE, Picardi M, Catalano L, Pane F.

   Retreatment with Bendamustine-Bortezomib-Dexamethasone in a patient with relapsed/refractory multiple myeloma

   Case Rep Hematol. 2016; 2016: 6745286.

10. Cerchione C, Cerciello G, Avilia S, Della Pepa R, Pugliese N, Picardi M, Pane F, Catalano L.

    Management of iron overload in myelodysplastic syndromes: combined deferasirox and deferoxamine in a patient with liver disease

    Blood Transfus. 2016 Oct 24; 1-4.

11. Della Pepa R, Pagano L, Cerchione C, Pugliese N, Pane F, Picardi M.

    Reply to the letter to the editor "chronic disseminated candidiasis" by Kenneth Rolston

    Support Care Cancer. 2017 Apr; 25(4): 1045-1046.

12. Pugliese N, Di Perna M, Cozzolino I, Ciancia G, Pettinato G, Zeppa P, Varone V, Masone S, Cerchione C, Della Pepa R, Simeone L, Salvatore C, Pane F, Picardi M.

    Randomized comparison of power Doppler ultrasonography-guided core-needle biopsy with open surgical biopsy for the characterization of lymphadenopathies in patients with suspected lymphoma

    Ann Hematol. 2017 Apr; 96(4): 627-637.

13. Cerchione C, Peluso I, Nappi D, Pareto AE, Picardi M, Martinelli V, Pane F.

    Ruxolitinib rechallenge in combination with hydroxyurea is effective in reverting cachexia and reducing blood transfusion demand and splenomegaly symptoms in a patient with primary myelofibrosis

    Ann Hematol. 2017 Apr; 96(4): 697-699.

14. Cerchione C, Nappi D, Di Perna M, Zacheo I, Migliaccio I, Salvatore D, Picardi M, Pane F, Catalano L.

    A case of efficacy of bendamustine in heavily pretreated multiple myeloma, refractory to pomalidomide

    Clinical Case reports, Vol 5, Issue 4, April 2017 Pages 505-507.

15. Cerchione C, Maraolo AE, Marano L, Pugliese N, Nappi D, Tosone G, Cimmino I, Cozzolino I, Martinelli V, Pane F, Picardi M.

    Secondary syphilis mimicking malignancy: A case report and review of literature

    J Infect Chemother. 2017 Aug; 23(8): 576-578.

16. Pugliese N, Salvatore P, Iula VD, Catania MR, Chiurazzi F, Della Pepa R, Cerchione C, Raimondo M, Giordano C, Simeone L, Caruso S, Pane F, Picardi M.

    Ultrasonography-driven tigecycline-based antibiotic therapy significantly increases survival among patients with neutropenic enterocolitis following cytarabine-containing chemotherapy for the remission induction of acute myeloid leukemia

    Cancer Med. 2017. Jul; 6(7): 1500-1511.

17. Fiore M, Maraolo AE, Chiodini P, Cerchione C, Gentile I, Borgia G, Pace MC.

    Is anticoagulation with novel oral anticoagulants an effective treatment for tubercolosis patients not achieving a therapeutic range with vitamin k antagonists? A Systematic Review.

    Cardiovasc Hematol Disord Drug Targets. 2017; 17(2): 105-110.

18. Della Pepa R, Picardi M, Giordano C, Zacheo I, Pugliese N, Cerchione C, Raimondo M, Di Perna M, Troncone G, Ciancia G, Intrieri M, Pane F.

    Rituximab in a risk-adapted treatment strategy gives excellent therapeutic results in nodular lyphocyte-predominant Hodgkin lymphoma

    Br J Haematol. 2017 Jul 24.

19. Mondello P, Steiner N, WIllenbacher W, Cerchione C, Nappi D, Mauro E, Ferrero S, Cuzzocrea S, Mian M.

    Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.

    Oncologist. 2018 Jan 9.

20. Romano A, Laura Parrinello N, Cerchione C, Letizia Consoli M, Parisi M, Calafiore V, Martino E, Conticello C, Di Raimondo F, Alberto Palumbo G.

    The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents.

    Blood Cancer J. 2017 Dec 15; 7(12): 649.

21. Romano A, Cerchione C, Consoli M, Parisi M, Calafiore V, Martino E, Conticello C, Di Raimondo F, Palumbo G

    The neutrophil-lymphocyte ratio (NLR) and the lymphocyte-monocyte ratio (LMR) predict progression free survival in patients with newly diagnosed multiple myeloma treated upfront with novel agents

    Blood Cancer J. 2017 Dec 15; 7(12): 649.

22. Cerchione C, Nappi D, Pareto AE, Romano A, Picardi M, Pane F, Catalano L

    Lenalidomide at the dose of twenty-five mg every other day in patients affected by multiple myeloma and renal failure: a real-life experience

    Anticancer Drugs. 2018 Feb 7.

23. Della Pepa R, Cerchione C, Pugliese N, Colicchio R, Salvatore P, Sirignano C, Soscia E, Pagano L, Sanguinetti M, Pane F, Picardi M.

    Diagnostic-driven antifungal approach in neutropenic patients at high risk for chronic disseminated candidiasis: preliminary osbservations on role of 1,3-beta-D-glucan antigenemia and multiphasic contrast-enhanced computed tomography

    Support Care Cancer. 2018 Mar 9.

24. Cerchione C, Nappi D, Pareto AE, Di Perna M, Zacheo I, Picardi M, Pane F, Catalano L

    Safety and comfort of domestic bortezomib injection in real life experience

    Support Care Cancer 2018 Mar 24.

25. Cerchione C, De Renzo A, Nappi D, Di Perna M, Della Pepa R, Pugliese N, Catalano L, Pane F, Picardi M.

    Pegfilgrastim in primary prophylaxis of febrile neutropenia in elderly patients with hematological malignancies-bendamustine and G-CSF support.

    Support Care Cancer 2019 Jan 23.

26. Picardi M, Della Pepa R, Cerchione C, Pugliese N, Mortaruolo C, Trastulli F, Giordano C, Grimaldi F, Zacheo I, Raimondo M, Chiurazzi F, Pane F.

    A Frontline Approach With Peripherally Inserted Versus Centrally Inserted Central Venous Catheters for Remission Induction Chemotherapy Phase of Acute Myeloid Leukemia: A Randomized Comparison.

    Clin Lymphoma Myeloma Leuk. 2019 Apr;19(4):e184-e194. doi: 10.1016/j.clml.2018.12.008. Epub 2018 Dec 20.

27. Pugliese N, Giordano C, Nappi D, Luciano L, Cerchione C, Annunziata M, Casale B, Crisà E, Villa MR, Pezzullo L, Iovine M, Picardi M, Grimaldi F, Pane F, Martinelli V.

    Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis.

    Cancer Med. 2019 Jun;8(6):2802-2809. doi: 10.1002/cam4.2147. Epub 2019 Apr 17.

28. Schepisi G, Cursano MC, Casadei C, Menna C, Altavilla A, Lolli C, Cerchione C, Paganelli G, Santini D, Tonini G, Martinelli G, De Giorgi U.

    CAR-T cell therapy: a potential new strategy against prostate cancer.

    J Immunother Cancer. 2019 Oct 16;7(1):258. doi: 10.1186/s40425-019-0741-7. Review.

29. Cerchione C, Martinelli G, Pedatella S, De Nisco M, Pugliese N, Manfra M, Marra N, Ronconi S, De Giorgi U, Altini M, Simonetti G, Di Rorà AGL, Bravaccini S, Catalano L, Dora Iula V, Pagano F, Picardi M, Bolognese A, Pane F, Martinelli V.

    An 1H NMR study of the cytarabine degradation in clinical conditions to avoid drug waste, decrease therapy costs and improve patient compliance in acute leukemia.

    Anticancer Drugs. 2020 Jan;31(1):67-72. doi: 10.1097/CAD.0000000000000850;

30. Claudio Cerchione, Giovanni Martinelli, Marco Picardi, Novella Pugliese, Davide Nappi, Aniello Casoria, Angela Gravetti, Delia Cangini, Maria Benedetta Giannini, Sonia Ronconi, Giorgia Simonetti, Andrea Ghelli Luserna Di Rorà, Ugo De Giorgi, Mattia Altini, Sara Bravaccini, Ilaria Santoriello, Cristiano Minucci, Fabrizio Pane and Vincenzo Martinelli.

    Combined oral fentanyl citrate and midazolam as premedication for bone marrow aspiration and biopsy in patients with hematological malignancies: a randomized, controlled and patient-blinded clinical trial

    J Clin Med. 2020 Feb 1;9(2):395. doi: 10.3390/jcm9020395.

31. Gentile M, Specchia G, Derudas D, Galli M, Botta C, Rocco S, Conticello C, Califano C, Giuliani N, Mangiacavalli S, Attingenti E, Lombardo A, Brunori M, Rossi E, Antonioli E, Ria R, Zambello R, Di Renzo N, Mele G, Marcacci G, Musto P, Capalbo S, Cascavilla N, Cerchione C, Belotti A, Criscuolo C, Uccello G, Curci P, Vigna E, Fraticelli V, Vincelli D, Bonalumi A, Siniscalchi A, Stocchi R, Martino M, Ballanti S, Gangemi D, Gagliardi A, Gamberi B, Pompa A, Recchia AG, Tripepi G, Pitino A, Frigeri F, Consoli U, Bringhen S, Zamagni E, Patriarca F, De Stefano V, Di Raimondo F, Palmieri S, Petrucci MT, Offidani M, Boccadoro M, Cavo M, Morabito F.

    Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials. Haematologica. 2020 Feb 27:haematol.2019.241513. doi: 10.3324/haematol.2019.241513. Online ahead of print.

32. Mondello P, Musolino C, Dogliotti I, Bohn JP, Cavallo F, Ferrero S, Botto B, Cerchione C, Nappi D, De Lorenzo S, Martinelli G, Wolf D, Schmitt C, Loseto G, Cuzzocrea S, Willenbacher W, Mian M, Straus DJ

    ABVD vs BEACOPP escalated in advanced-stage Hodgkin's lymphoma: Results from a multicenter European study.

    Am J Hematol. 2020 May 17. doi: 10.1002/ajh.25871. Online ahead of print.

33. Lucchesi A, Silimbani P, Musuraca G, Cerchione C, Martinelli G, Di Carlo P, Napolitano M.

    Clinical and biological data on the use of hydroxychloroquine against SARS-CoV-2 could support the role of the NLRP3 inflammasome in the pathogenesis of respiratory disease.

    J Med Virol. 2020 Jun 24:10.1002/jmv.26217. doi: 10.1002/jmv.26217. Online ahead of print.

34. Palmieri S, Rocco S, Vitagliano O, Catalano L, Cerchione C, Vincelli ID, Scopelliti A, Gentile M, Farina G, Barone M, Gagliardi A, Esposito D, Arcamone M, Amico V, Fontana R, Sementa A, Sica A, Svanera G, Pane F, Ferrara F.

    KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients.

    Ann Hematol. 2020 Jun 25. doi: 10.1007/s00277-020-04158-4. Online ahead of print.

35. Nolan S, Vignali M, Klinger M, Dines JN, Kaplan IM, Svejnoha E, Craft T, Boland K, Pesesky M, Gittelman RM, Snyder TM, Gooley CJ, Semprini S, Cerchione C, Mazza M, Delmonte OM, Dobbs K, Carreño-Tarragona G, Barrio S, Sambri V, Martinelli G, Goldman JD, Heath JR, Notarangelo LD, Carlson JM, Martinez-Lopez J, Robins HS.

    A large-scale database of T-cell receptor beta (TCRβ) sequences and binding associations from natural and synthetic exposure to SARS-CoV-2.

    Res Sq. 2020 Aug 4:rs.3.rs-51964. doi: 10.21203/rs.3.rs-51964/v1. Preprint.

36. Snyder TM, Gittelman RM, Klinger M, May DH, Osborne EJ, Taniguchi R, Zahid HJ, Kaplan IM, Dines JN, Noakes MN, Pandya R, Chen X, Elasady S, Svejnoha E, Ebert P, Pesesky MW, De Almeida P, O'Donnell H, DeGottardi Q, Keitany G, Lu J, Vong A, Elyanow R, Fields P, Greissl J, Baldo L, Semprini S, Cerchione C, Mazza M, Delmonte OM, Dobbs K, Carreño-Tarragona G, Barrio S, Imberti L, Sottini A, Quiros-Roldan E, Rossi C, Biondi A, Bettini LR, D'Angio M, Bonfanti P, Tompkins MF, Alba C, Dalgard C, Sambri V, Martinelli G, Goldman JD, Heath JR, Su HC, Notarangelo LD, Martinez-Lopez J, Carlson JM, Robins HS.

    Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels.

    medRxiv. 2020 Aug 4:2020.07.31.20165647. doi: 10.1101/2020.07.31.20165647. Preprint.

37. Cerchione C, Nappi D, Musuraca G, Lucchesi A, Cimmino I, Pane F, De Renzo A, Martinelli G.

    Can early switch to rituximab-bendamustine in a patient with follicular non-Hodgkin lymphoma progressing during R-CHOP be considered frontline treatment?: A case report.

    Medicine (Baltimore). 2020 Aug 14;99(33):e21440. doi: 10.1097/MD.0000000000021440.

38. Bravaccini S, Martinelli G, Cerchione C.

    What Influences the Choice of Ibrutinib-Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia?

    Cell Transplant. 2020 Jan-Dec;29:963689720950209. doi: 10.1177/0963689720950209.

39. Ricciuti G, Falcone AP, Cascavilla N, Martinelli G, Cerchione C.

    Autologous stem cell transplantation in multiple myeloma.

    Panminerva Med. 2020 Sep 21. doi: 10.23736/S0031-0808.20.04114-2. Online ahead of print.

40. Nagarajan C, Tan MS, Chen Y, Martinelli G, Cerchione C.

    Current and future perspectives of maintenance therapy in multiple myeloma.

    Panminerva Med. 2020 Sep 21. doi: 10.23736/S0031-0808.20.04117-8. Online ahead of print.

41. Chen Y, Nagarajan C, Tan MS, Martinelli G, Cerchione C.

    BCMA-targeting approaches for treatment of multiple myeloma.

    Panminerva Med. 2020 Sep 21. doi: 10.23736/S0031-0808.20.04121-X. Online ahead of print.

42. Derudas D, Capraro F, Martinelli G, Cerchione C.

    Old and new generation immunomodulatory drugs in multiple myeloma.

    Panminerva Med. 2020 Sep 21. doi: 10.23736/S0031-0808.20.04125-7. Online ahead of print.

43. Santoro M, Romano A, Mancuso S, Siragusa S, Di Raimondo F, Martinelli G, Cerchione C.

    Prevention of venous thromboembolic events occurring in myeloma patients treated with second-generation novel agents.

    Panminerva Med. 2020 Sep 21. doi: 10.23736/S0031-0808.20.04133-6. Online ahead of print.

44. Romano A, Santoro M, Conticello C, Siragusa S, Di Raimondo F, Martinelli G, Cerchione C.

    Post-transplant consolidation based on combination of lenalidomide and proteasome inhibitors in multiple myeloma.

    Panminerva Med. 2020 Sep 21. doi: 10.23736/S0031-0808.20.04141-5. Online ahead of print.

45. Martino M, Paviglianiti A, Gentile M, Martinelli G, Cerchione C.

    Allogenic stem cell transplantation in multiple myeloma: dead or alive and kicking?

    Panminerva Med. 2020 Sep 21. doi: 10.23736/S0031-0808.20.04142-7. Online ahead of print.

46. Gentile M, Morabito F, Martino M, Vigna E, Martino EA, Mendicino F, Martinelli G, Cerchione C.

    Chemotherapy-based regimens in multiple myeloma in 2020.

    Panminerva Med. 2020 Sep 21. doi: 10.23736/S0031-0808.20.04145-2. Online ahead of print.

47. Nicolini F, Bravaccini S, Mazza M, Gruszka AM, Tazzari M, Martín-Antonio B, Juan M, Ibrahim T, Maltoni R, Martinelli G, Cerchione C.

    CAR T cells targeting options in the fight against multiple myeloma.

    Panminerva Med. 2020 Sep 21. doi: 10.23736/S0031-0808.20.04146-4. Online ahead of print.

48. Vozella F, Fazio F, Lapietra G, Petrucci MT, Martinelli G, Cerchione C.

    Monoclonal antibodies in multiple myeloma.

    Panminerva Med. 2020 Sep 21. doi: 10.23736/S0031-0808.20.04149-X. Online ahead of print.

49. Mosquera Orgueira A, Bao Pérez L, Mosquera Torre A, Peleteiro Raíndo A, Cid López M, Diaz Arias JA, Ferreiro Ferro R, Antelo Rodriguez B, González Pérez MS, Albors Ferreiro M, Alonso Vence N, Pérez Encinas MM, Bello López JL, Martinelli G, Cerchione C.

    FLT3 inhibitors in the treatment of Acute Myeloid Leukemia: current status and future perspectives.

    Minerva Med. 2020 Sep 21. doi: 10.23736/S0026-4806.20.06989-X. Online ahead of print.

50. Abdul-Hamil NA, Wong GC, Nagarajan C, Martinelli G, Cerchione C.

    Midostaurin in acute myeloid leukemia: review of current evidence and practical considerations in routine clinical use.

    Minerva Med. 2020 Sep 21. doi: 10.23736/S0026-4806.20.07014-7. Online ahead of print.

51. Palmieri R, Buccisano F, Maurillo L, Del Principe MI, Paterno G, Venditti A, Martinelli G, Cerchione C.

    Current strategies for detection and approach to easurable residual disease in Acute Myeloid Leukemia.

    Minerva Med. 2020 Sep 21. doi: 10.23736/S0026-4806.20.07016-0. Online ahead of print.

52. Cafaro A, Giannini MB, Silimbani P, Cangini D, Masini C, Ghelli Luserna Di Rorá A, Simonetti G, Martinelli G, Cerchione C.

    CPX-351 - Daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia.

    Minerva Med. 2020 Sep 21. doi: 10.23736/S0026-4806.20.07017-2. Online ahead of print.

53. Cangini D, Silimbani P, Cafaro A, Giannini MB, Masini C, Ghelli Luserna Di Rorá A, Simonetti G, Martinelli G, Cerchione C.

    Tagraxofusp and anti-CD123 in blastic plasmacytoid dendritic cell neoplasm: a new hope.

    Minerva Med. 2020 Sep 21. doi: 10.23736/S0026-4806.20.07018-4. Online ahead of print.

54. Gottardi M, Sperotto A, Ghelli Luserna Di Rorá A, Padella A, Cangini D, Giannini MB, Simonetti G, Martinelli G, Cerchione C.

    Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and feature.

    Minerva Med. 2020 Sep 21. doi: 10.23736/S0026-4806.20.07019-6. Online ahead of print.

55. Martelli MP, Martino G, Cardinali V, Falini B, Martinelli G, Cerchione C.

    Enasidenib and Ivosidenib in AML.

    Minerva Med. 2020 Sep 21. doi: 10.23736/S0026-4806.20.07024-X. Online ahead of print.

56. Lanza F, Maffini E, Saraceni F, Massari E, Rondoni M, Daghia G, Olivieri A, Cerchione C amd Martinelli G.

    New monoclonal antibodies and tyrosine kinase inhibitors in B-cell acute lymphoblastic leukemia.

    Minerva Med. 2020 Sep 21. doi: 10.23736/S0026-4806.20.07031-7. Online ahead of print.

57. Cerchione C, Martinelli G.

    Acute leukemias in 2020: state of the art.

    Minerva Med. 2020 Sep 22. doi: 10.23736/S0026-4806.20.07049-4. Online ahead of print.

58. Montefusco V, Mussetti A, Sala MR, Martinelli G, Cerchione C.

    Old and new generation proteasome inhibitors in multiple myeloma.

    Panminerva Med. 2020 Sep 22. doi: 10.23736/S0031-0808.20.04148-8. Online ahead of print.

59. Cerchione C, Martinelli G.

    Multiple myeloma in 2020: state of the art.

    Panminerva Med. 2020 Sep 22. doi: 10.23736/S0031-0808.20.04159-2. Online ahead of print.

60. Ghelli Luserna di Rorà A, Cerchione C, Martinelli G, Simonetti G.

    A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target.

    J Hematol Oncol. 2020 Sep 21;13(1):126. doi: 10.1186/s13045-020-00959-2.

61. Molica M, Noguera NI, Trawinska MM, Martinelli G, Cerchione C and Abruzzese E.

    Treatment free remission in chronic myeloid leukemia: Lights and shadows.

    Hematol Rep. 2020 Sep 21;12(Suppl 1):8950. doi: 10.4081/hr.2020.8950. eCollection 2020 Sep 21.

62. Romano A, Cerchione C, Conticello C, Martinelli G, Di Raimondo F.

    How we manage smoldering multiple myeloma.

    Hematol Rep. 2020 Sep 21;12(Suppl 1):8951. doi: 10.4081/hr.2020.8951. eCollection 2020 Sep 21.

63. Montefusco V, Martinelli G, Cerchione C.

    How I manage frontline transplant-eligible multiple myeloma in Italy.

    Hematol Rep. 2020 Sep 21;12(Suppl 1):8954. doi: 10.4081/hr.2020.8954. eCollection 2020 Sep 21.

64. Lee HC, Cerchione C.

    How I treat relapsed and/or refractory multiple myeloma.

    Hematol Rep. 2020 Sep 21;12(Suppl 1):8955. doi: 10.4081/hr.2020.8955. eCollection 2020 Sep 21.

65. Derudas D, Capraro F, Martinelli G, Cerchione C.

    How I manage frontline transplant-ineligible multiple myeloma.

    Hematol Rep. 2020 Sep 21;12(Suppl 1):8956. doi: 10.4081/hr.2020.8956. eCollection 2020 Sep 21.

66. Ravaioli S, Tebaldi M, Fonzi E, Angeli D, Mazza M, Nicolini F, Lucchesi A, Fanini F, Pirini F, Tumedei MM, Cerchione C, Viale P, Sambri V, Martinelli G, Bravaccini S.

    ACE2 and TMPRSS2 Potential Involvement in Genetic Susceptibility to SARS-COV-2 in Cancer Patients.

    Cell Transplant. 2020 Jan-Dec;29:963689720968749. doi: 10.1177/0963689720968749.

67. Martino M, Paviglianiti A, Memoli M, Martinelli G, Cerchione C,

    Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art

    Front. Oncol. | doi: 10.3389/fonc.2020.592487

68. Monti M, Vertogen B, Masini C, Donati C, Lilli C, Zingaretti C, Musuraca G, De Giorgi U, Cerchione C, Farolfi A, Cortesi P, Viale P, Martinelli G, Nanni O

    Hydroxychloroquine as prophylaxis for COVID-19: a review

    Front Pharmacol. 2020 Dec 3;11:605185. doi: 10.3389/fphar.2020.605185. eCollection 2020.

69. Offidani M, Corvatta L, Morè S, Nappi D, Martinelli G, Olivieri A, Cerchione C.

    Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments.

    Front Oncol. 2021 Feb 17;10:624661. doi: 10.3389/fonc.2020.624661. eCollection 2020.

70. Martino M, Alati C, Canale FA, Musuraca G, Martinelli G, Cerchione C.

    A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia.

    Int J Mol Sci. 2021 Feb 21;22(4):2150. doi: 10.3390/ijms22042150.

71. Cimmino I, Bravaccini S, Cerchione C.

    Urinary Biomarkers in Tumors: An Overview.

    Methods Mol Biol. 2021;2292:3-15. doi: 10.1007/978-1-0716-1354-2_1.

72. Kaufman GP, Cerchione C.

    Beyond Andromeda: Improving Therapy for Light Chain Amyloidosis.

    Front Oncol. 2021 Feb 3;10:624573. doi: 10.3389/fonc.2020.624573. eCollection 2020.

73. Matteucci F, Paganelli G, Martinelli G, Cerchione C.

    PET/CT in Multiple Myeloma: Beyond FDG.

    Front Oncol. 2021 Jan 25;10:622501. doi: 10.3389/fonc.2020.622501. eCollection 2020.

74. Mosquera Orgueira A, Peleteiro Raíndo A, Cid López M, Antelo Rodríguez B, Díaz Arias JÁ, Ferreiro Ferro R, Alonso Vence N, Bendaña López Á, Abuín Blanco A, Bao Pérez L, Melero Valentín P, González Pérez MS, Cerchione C, Martinelli G, Montesinos Fernández P, Pérez Encinas MM, Bello López JL.

    Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia.

    PLoS One. 2021 Feb 16;16(2):e0247093. doi: 10.1371/journal.pone.0247093. eCollection 2021.

75. Bolli N, Martinelli G, Cerchione C.

    The molecular pathogenesis of multiple myeloma.

    Hematol Rep. 2020 Dec 18;12(3):9054. doi: 10.4081/hr.2020.9054. eCollection 2020 Dec 2.

    PMID: 33408844 Free PMC article.

76. Zannetti BA, Faini AC, Massari E, Geuna M, Maffini E, Poletti G, Cerchione C, Martinelli G, Malavasi F, Lanza F.

    Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model.

    Cells. 2020 Dec 11;9(12):2666. doi: 10.3390/cells9122666.

77. Rossi A, Prochowski Iamurri A, Cerchione C, Gentili N, Danesi V, Altini M, Paganelli G, Barone D.

    Radiology imaging management in an Italian cancer center (IRST IRCCS) during the COVID-19 pandemic.

    Insights Imaging. 2020 Dec 3;11(1):129. doi: 10.1186/s13244-020-00935-x.

78. Martino M, Paviglianiti A, Memoli M, Martinelli G, Cerchione C.

    Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art.

    Front Oncol. 2020 Nov 11;10:592487. doi: 10.3389/fonc.2020.592487. eCollection 2020.

79. Picardi M, Giordano C, Della Pepa R, Cerchione C, Pugliese N, Leone A, Vitiello S, Pane F.

    Correspondence in reference to previously published manuscript: "Faouzi Djebbari et al. Efficacy and infection morbidity of front-line immuno-chemotherapy in follicular lymphoma.

    Eur J Haematol. 2020; 105: 667-671".

    Eur J Haematol. 2020 Nov 30. doi: 10.1111/ejh.13558. Online ahead of print.

80. Martino M, Paviglianiti A, Memoli M, Martinelli G, Cerchione C.

    Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art.

    Front Oncol. 2020 Nov 11;10:592487. doi: 10.3389/fonc.2020.592487. eCollection 2020.

81. Rossi A, Prochowski Iamurri A, Cerchione C, Gentili N, Danesi V, Altini M, Paganelli G, Barone D.

    Radiology imaging management in an Italian cancer center (IRST IRCCS) during the COVID-19 pandemic.

    Insights Imaging. 2020 Dec 3;11(1):129. doi: 10.1186/s13244-020-00935-x.

    PMID: 33270166 Free PMC article. Review.

82. Zannetti BA, Faini AC, Massari E, Geuna M, Maffini E, Poletti G, Cerchione C, Martinelli G, Malavasi F, Lanza F.

    Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model.

    Cells. 2020 Dec 11;9(12):2666. doi: 10.3390/cells9122666.

83. Monti M, Vertogen B, Masini C, Donati C, Lilli C, Zingaretti C, Musuraca G, De Giorgi U, Cerchione C, Farolfi A, Cortesi P, Viale P, Martinelli G, Nanni O.

    Hydroxychloroquine as Prophylaxis for COVID-19: A Review.

    Front Pharmacol. 2020 Dec 3;11:605185. doi: 10.3389/fphar.2020.605185. eCollection 2020.

84. Bolli N, Martinelli G, Cerchione C.

    The molecular pathogenesis of multiple myeloma.

    Hematol Rep. 2020 Dec 18;12(3):9054. doi: 10.4081/hr.2020.9054. eCollection 2020 Dec 2.

85. Mosquera Orgueira A, Peleteiro Raíndo A, Cid López M, Antelo Rodríguez B, Díaz Arias JÁ, Ferreiro Ferro R, Alonso Vence N, Bendaña López Á, Abuín Blanco A, Bao Pérez L, Melero Valentín P, González Pérez MS, Cerchione C, Martinelli G, Montesinos Fernández P, Pérez Encinas MM, Bello López JL.

    Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia.

    PLoS One. 2021 Feb 16;16(2):e0247093. doi: 10.1371/journal.pone.0247093. eCollection 2021.

    PMID: 33592069 Free PMC article.

86. Matteucci F, Paganelli G, Martinelli G, Cerchione C.

    PET/CT in Multiple Myeloma: Beyond FDG.

    Front Oncol. 2021 Jan 25;10:622501. doi: 10.3389/fonc.2020.622501. eCollection 2020.

87. Kaufman GP, Cerchione C.

    Beyond Andromeda: Improving Therapy for Light Chain Amyloidosis.

    Front Oncol. 2021 Feb 3;10:624573. doi: 10.3389/fonc.2020.624573. eCollection 2020.

    PMID: 33614504 Free PMC article. Review.

88. Cimmino I, Bravaccini S, Cerchione C.

    Urinary Biomarkers in Tumors: An Overview.

    Methods Mol Biol. 2021;2292:3-15. doi: 10.1007/978-1-0716-1354-2_1.

89. Martino M, Alati C, Canale FA, Musuraca G, Martinelli G, Cerchione C.

    A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia.

    Int J Mol Sci. 2021 Feb 21;22(4):2150. doi: 10.3390/ijms22042150.

    PMID: 33670075 Free PMC article. Review.

90. Offidani M, Corvatta L, Morè S, Nappi D, Martinelli G, Olivieri A, Cerchione C.

    Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments.

    Front Oncol. 2021 Feb 17;10:624661. doi: 10.3389/fonc.2020.624661. eCollection 2020.

91. Cerchione C, Locatelli F, Martinelli G.

    Dasatinib in the Management of Pediatric Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

    Front Oncol. 2021 Mar 25;11:632231. doi: 10.3389/fonc.2021.632231. eCollection 2021.

    PMID: 33842339 Free PMC article. Review.

92. Marconi G, Giannini MB, Bagnato G, Simonetti G, Cerchione C, Mosquera Orgueira A, Musuraca G, Martinelli G.

    The safety profile of FLT3 inhibitors in the treatment of newly diagnosed or relapsed/refractory acute myeloid leukemia.

    Expert Opin Drug Saf. 2021 Apr 14:1-9. doi: 10.1080/14740338.2021.1913120.

93. Mosquera Orgueira A, Peleteiro Raíndo A, Cid López M, Díaz Arias JÁ, González Pérez MS, Antelo Rodríguez B, Alonso Vence N, Bao Pérez L, Ferreiro Ferro R, Albors Ferreiro M, Abuín Blanco A, Fontanes Trabazo E, Cerchione C, Martinnelli G, Montesinos Fernández P, Mateo Pérez Encinas M, Luis Bello López J.

    Personalized Survival Prediction of Patients With Acute Myeloblastic Leukemia Using Gene Expression Profiling.

    Front Oncol. 2021 Mar 29;11:657191. doi: 10.3389/fonc.2021.657191. eCollection 2021.

94. Cerchione C, Romano A, Daver N, DiNardo C, Jabbour EJ, Konopleva M, Ravandi-Kashani F, Kadia T, Martelli MP, Isidori A, Martinelli G, Kantarjian H.

    IDH1/IDH2 Inhibition in Acute Myeloid Leukemia.

    Front Oncol. 2021 Mar 29;11:639387. doi: 10.3389/fonc.2021.639387. eCollection 2021.

95. Picardi M, Cavaliere C, Della Pepa R, Nicolai E, Soricelli A, Giordano C, Pugliese N, Rascato MG, Cappuccio I, Campagna G, Cerchione C, Vigliar E, Troncone G, Mascolo M, Franzese M, Castaldo R, Salvatore M, Pane F

    PET/MRI for staging patients with Hodgkin lymphoma: equivalent results with PET/CT in a prospective trial.

    Ann Hematol. 2021 Jun;100(6):1525-1535. doi: 10.1007/s00277-021-04537-5. Epub 2021 Apr 28.

96. Botta C, Martino EA, Conticello C, Mendicino F, Vigna E, Romano A, Palumbo GA, Cerchione C, Martinelli G, Morabito F, Di Raimondo F, Gentile M.

    Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens.

    Front Oncol. 2021 Apr 14;11:643490. doi: 10.3389/fonc.2021.643490. eCollection 2021.

97. Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma.

    Cerchione C, Nappi D, Martinelli G.

    Support Care Cancer. 2021 May 14. doi: 10.1007/s00520-021-06266-x. Online ahead of print.

    PMID: 33990881 Review.

98. Isidori A, Cerchione C, Daver N, DiNardo C, Garcia-Manero G, Konopleva M, Jabbour E, Ravandi F, Kadia T, Burguera AF, Romano A, Loscocco F, Visani G, Martinelli G, Kantarjian H, Curti A.

    Immunotherapy in Acute Myeloid Leukemia: Where We Stand.

    Front Oncol. 2021 May 10;11:656218. doi: 10.3389/fonc.2021.656218. eCollection 2021.

    PMID: 34041025 Free PMC article. Review.

99. Martino M, Canale FA, Alati C, Vincelli ID, Moscato T, Porto G, Loteta B, Naso V, Mazza M, Nicolini F, Ghelli Luserna di Rorà A, Simonetti G, Ronconi S, Ceccolini M, Musuraca G, Martinelli G, Cerchione C.

    CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma.

    Cancers (Basel). 2021 May 27;13(11):2639. doi: 10.3390/cancers13112639.

    PMID: 34072068 Free PMC article. Review.

100. Simonetti G, Angeli D, Petracci E, Fonzi E, Vedovato S, Sperotto A, Padella A, Ghetti M, Ferrari A, Robustelli V, Di Liddo R, Conconi MT, Papayannidis C, Cerchione C, Rondoni M, Astolfi A, Ottaviani E, Martinelli G, Gottardi M.

     Adrenomedullin Expression Characterizes Leukemia Stem Cells and Associates With an Inflammatory Signature in Acute Myeloid Leukemia.

     Front Oncol. 2021 Jun 2;11:684396. doi: 10.3389/fonc.2021.684396. eCollection 2021.

     PMID: 34150648 Free PMC article.

101. Cerchione C, Peleteiro Raíndo A, Mosquera Orgueira A, Mosquera Torre A, Bao Pérez L, Marconi G, Isidori A, Pérez Encinas MM, Martinelli G.

     Safety of FLT3 inhibitors in patients with acute myeloid leukemia.

     Expert Rev Hematol. 2021 Sep;14(9):851-865. doi: 10.1080/17474086.2021.1969911. Epub 2021 Aug 30.

     PMID: 34424108

102. Ghelli Luserna Di Rorà A, Ghetti M, Ledda L, Ferrari A, Bocconcelli M, Padella A, Napolitano R, Fontana MC, Liverani C, Imbrogno E, Bochicchio MT, Paganelli M, Robustelli V, Sanogo S, Cerchione C, Fumagalli M, Rondoni M, Imovilli A, Musuraca G, Martinelli G, Simonetti G.

     Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells.

     Cell Biol Toxicol. 2021 Sep 14. doi: 10.1007/s10565-021-09640-x. Online ahead of print. PMID: 34519926

103. Gottardi M, Simonetti G, Sperotto A, Nappi D, Ghelli Luserna di Rorà A, Padella A, Norata M, Giannini MB, Musuraca G, Lanza F, Cerchione C, Martinelli G.

     Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin.

     Cancers (Basel). 2021 Sep 11;13(18):4566. doi: 10.3390/cancers13184566. PMID: 34572794 Free article. Review.

104. Martino M, Pitino A, Gori M, Bruno B, Crescimanno A, Federico V, Picardi A, Tringali S, Ingrosso C, Carluccio P, Pastore D, Musuraca G, Paviglianiti A, Vacca A, Serio B, Storti G, Mordini N, Leotta S, Cimminiello M, Prezioso L, Loteta B, Ferreri A, Colasante F, Merla E, Giaccone L, Busca A, Musso M, Scalone R, Di Renzo N, Marotta S, Mazza P, Musto P, Attolico I, Selleri C, Canale FA, Pugliese M, Tripepi G, Porto G, Martinelli G, Carella AM Jr, Cerchione C

     Letermovir Prophylaxis for Cytomegalovirus Infection in Allogeneic Stem Cell Transplantation: A Real-World Experience. Front Oncol. 2021 Sep 6;11:740079. doi: 10.3389/fonc.2021.740079. eCollection 2021.PMID: 34616684

105. Pallotti MC, Rossi R, Scarpi E, Dall'Agata M, Ricci M, Ceccolini M, Ronconi S, Valenti V, Maltoni M, Martinelli G, Cerchione C.

     Patients with multiple myeloma referred for palliative care consultation: from retrospective analysis to future directions to improve clinical outcomes.

     Support Care Cancer. 2022 Mar;30(3):2293-2298. doi: 10.1007/s00520-021-06560-8. Epub 2021 Oct 31. PMID: 34718886

106. Maltoni R, Ravaioli S, Bronte G, Mazza M, Cerchione C, Massa I, Balzi W, Cortesi M, Zanoni M, Bravaccini S.

     Chronological age or biological age: What drives the choice of adjuvant treatment in elderly breast cancer patients?

     Transl Oncol. 2022 Jan;15(1):101300. doi: 10.1016/j.tranon.2021.101300. Epub 2021 Dec 1. PMID: 34864401

107. Mosquera Orgueira A, Cid López M, Peleteiro Raíndo A, Abuín Blanco A, Díaz Arias JÁ, González Pérez MS, Antelo Rodríguez B, Bao Pérez L, Ferreiro Ferro R, Aliste Santos C, Pérez Encinas MM, Fraga Rodríguez MF, Cerchione C, Mozas P, Bello López JL.

     Personally Tailored Survival Prediction of Patients With Follicular Lymphoma Using Machine Learning Transcriptome-Based Models.

     Front Oncol. 2022 Jan 10;11:705010. doi: 10.3389/fonc.2021.705010. eCollection 2021. PMID: 35083135

108. Cerchione C, Usmani SZ, Stewart AK, Kaiser M, Rasche L, Kortüm M, Mateos MV, Spencer A, Sonneveld P, Anderson KC.

     Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment

     Front Oncol. 2022 Feb 8;12:820768. doi: 10.3389/fonc.2022.820768. eCollection 2022.cPMID: 35211412

109. Romano A, Cerchione C, Conticello C, Filetti S, Bulla A, Chiarenza A, Del Fabro V, Leotta S, Markovic U, Motta G, Parisi M, Stagno F, Palumbo GA, Di Raimondo F.

     Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 Infection.

     Cancers (Basel). 2022 Feb 24;14(5):1173. doi: 10.3390/cancers14051173. PMID: 35267478

110. Bruzzese A, Derudas D, Galli M, Martino EA, Rocco S, Conticello C, Califano C, Giuliani N, Mangiacavalli S, Farina G, Lombardo A, Brunori M, Rossi E, Antonioli E, Ria R, Zambello R, Di Renzo N, Mele G, Marcacci G, Pietrantuono G, Palumbo G, Cascavilla N, Cerchione C, Belotti A, Criscuolo C, Uccello G, Curci P, Vigna E, Mendicino F, Iaccino E, Mimmi S, Botta C, Vincelli D, Sgherza N, Bonalumi A, Cupelli L, Stocchi R, Martino M, Ballanti S, Gangemi D, Gagliardi A, Gamberi B, Pompa A, Tripepi G, Frigeri F, Consoli U, Bringhen S, Zamagni E, Patriarca F, De Stefano V, Di Raimondo F, Palmieri S, Petrucci MT, Offidani M, Musto P, Boccadoro M, Cavo M, Neri A, Morabito F, Gentile M.

     Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials.

     Hematol Oncol. 2022 Oct;40(4):704-715. doi: 10.1002/hon.3031. Epub 2022 Jun 1. PMID: 35608183

111. Messina M, Piciocchi A, Ottone T, Paolini S, Papayannidis C, Lessi F, Fracchiolla NS, Forghieri F, Candoni A, Mengarelli A, Martelli MP, Venditti A, Carella AM, Albano F, Mancini V, Massimo B, Arena V, Sargentini V, Sciumè M, Pastore D, Todisco E, Roti G, Siragusa S, Ladetto M, Pravato S, De Bellis E, Simonetti G, Marconi G, Cerchione C, Fazi P, Vignetti M, Amadori S, Martinelli G, Voso MT.

     Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol.

     Cancers (Basel). 2022 Jun 18;14(12):3012. doi: 10.3390/cancers14123012. PMID: 35740677

112. Botta C, Gigliotta E, Paiva B, Anselmo R, Santoro M, Otero PR, Carlisi M, Conticello C, Romano A, Solimando AG, Cerchione C, Vià MD, Bolli N, Correale P, Di Raimondo F, Gentile M, San Miguel J, Siragusa S.

     Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant.

     Hematol Oncol. 2022 Dec;40(5):987-998. doi: 10.1002/hon.3041. Epub 2022 Jul 11. PMID: 35794705

113. Mazzotti L, Gaimari A, Bravaccini S, Maltoni R, Cerchione C, Juan M, Navarro EA, Pasetto A, Nascimento Silva D, Ancarani V, Sambri V, Calabrò L, Martinelli G, Mazza M.

     T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer.

     Int J Mol Sci. 2022 Aug 2;23(15):8590. doi: 10.3390/ijms23158590. PMID: 35955721

114. Pascale SP, Nuccorini R, Pierri T, Di Mare R, Fabio L, Lerose E, Merlino MA, Schiavo P, Amendola A, Brucoli G, Caputo MD, Chitarrelli I, Cimminiello M, Coluzzi S, Filardi NB, Matturro A, Vertone D, Poggiaspalla M, Malaspina F, Musuraca G, Coralluzzo G, Mannarella C, Musto C, Bellettieri AP, Martinelli G, Cerchione C, Pizzuti M.

     Evaluation of serological response to anti-SARS-CoV-2 mRNA vaccination in hematological patients.

     Front Immunol. 2022 Aug 8;13:892331. doi: 10.3389/fimmu.2022.892331. eCollection 2022. PMID: 36003404

115. Mosquera Orgueira A, Peleteiro Raíndo A, Díaz Arias JÁ, Antelo Rodríguez B, López Riñón M, Cerchione C, de la Fuente Burguera A, González Pérez MS, Martinelli G, Montesinos Fernández P, Pérez Encinas MM.

     Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia.

     Front Oncol. 2022 Aug 17;12:968340. doi: 10.3389/fonc.2022.968340. eCollection 2022. PMID: 36059646

116. Cerchione C, Nappi D, Romano A, Martinelli G.

     Pegfilgrastim in Supportive Care of Hodgkin Lymphoma.

     Cancers (Basel). 2022 Aug 23;14(17):4063. doi: 10.3390/cancers14174063. PMID: 36077600

117. Bravaccini S, Nicolini F, Zanoni M, Gaimari A, Cerchione C, Maltoni R, Pirini F, Mazzotti L, Cortesi M, Ravaioli S, Tumedei MM, Mazza M.

     Why the complications of COVID-19 patients differ in elderly and young cancer patients.

     Transl Oncol. 2022 Dec;26:101541. doi: 10.1016/j.tranon.2022.101541. Epub 2022 Sep 12. PMID: 36119944

118. Guolo F, Cerchione C, Vernarecci C, Isidori A.

     Editorial: Acute myeloid leukemia (AML): Is it time for MRD-driven treatment?

     Front Oncol. 2022 Sep 9;12:1020185. doi: 10.3389/fonc.2022.1020185. eCollection 2022. PMID: 36158678

119. Wilde L, Binder A, Cerchione C, Isidori A.

     Editorial: COVID-19 and hematological malignancies: Volume II.

     Front Oncol. 2022 Oct 10;12:1044582. doi: 10.3389/fonc.2022.1044582. eCollection 2022. PMID: 36300086

120. Martino M, Naso V, Loteta B, Canale FA, Pugliese M, Alati C, Musuraca G, Nappi D, Gaimari A, Nicolini F, Mazza M, Bravaccini S, Derudas D, Martinelli G, Cerchione C.

     Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon.

     Int J Mol Sci. 2022 Nov 1;23(21):13332. doi: 10.3390/ijms232113332. PMID: 36362130

121. Todisco E, Papayannidis C, Fracchiolla N, Petracci E, Zingaretti C, Vetro C, Martelli MP, Zappasodi P, Di Renzo N, Gallo S, Audisio E, Griguolo D, Cerchione C, Selleri C, Mattei D, Bernardi M, Fumagalli M, Rizzuto G, Facchini L, Basilico CM, Manfra I, Borlenghi E, Cairoli R, Salutari P, Gottardi M, Molteni A, Martini V, Lunghi M, Fianchi L, Cilloni D, Lanza F, Abruzzese E, Cascavilla N, Rivellini F, Ferrara F, Maurillo L, Nanni J, Romano A, Cardinali V, Gigli F, Roncoroni E, Federico V, Marconi G, Volpi R, Sciumè M, Tarella C, Rossi G, Martinelli G; AVALON Cooperative Group. 
     AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia.

Cancer. 2023 Jan 24. doi: 10.1002/cncr.34608. Online ahead of print. PMID: 36692409